Informatie:
Fout:
ID
20543
Beschrijving
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00672386
Link
https://clinicaltrials.gov/show/NCT00672386
Trefwoorden
Versies (1)
- 02-03-17 02-03-17 -
Geüploaded op
2 maart 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Diabetes Mellitus, Type 2 NCT00672386
Eligibility Diabetes Mellitus, Type 2 NCT00672386
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT00672386
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
type 2 diabetes mellitus, metformin
Item
history of type 2 diabetes mellitus and treated with a stable dose of metformin for at least 2 months
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0025598 (UMLS CUI [2])
Gender | Postmenopausal state | Childbearing Potential | Contraceptive methods
Item
women must be postmenopausal or surgically incapable of childbearing or if sexually active, be practicing an effective method of birth control
boolean
C0079399 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
C3831118 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
C0232970 (UMLS CUI [2])
C3831118 (UMLS CUI [3])
C0700589 (UMLS CUI [4])
bmi
Item
bmi between 25 and 45 kg/m2
boolean
C1305855 (UMLS CUI [1])
hba1c
Item
hba1c between 7% and 10%, inclusive
boolean
C0019018 (UMLS CUI [1])
fasting plasma glucose
Item
fasting plasma glucose not exceeding 240mg/dl (13.3mmol/l)
boolean
C0583513 (UMLS CUI [1])
diabetes type
Item
diabetes other than type 2 diabetes mellitus
boolean
C1320657 (UMLS CUI [1])
oral hypoglycemic, insulin
Item
treatment with oral anti-diabetic agents (other than metformin) or insulin during the 12 weeks before baseline visit
boolean
C0359086 (UMLS CUI [1])
C0021641 (UMLS CUI [2])
C0021641 (UMLS CUI [2])
intolerance or hypersensitivity to sulfonylurea or sitagliptin
Item
history of intolerance or hypersensitivity to sulfonylurea or sitagliptin
boolean
C0020517 (UMLS CUI [1,1])
C0038766 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1565750 (UMLS CUI [2,2])
C0038766 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1565750 (UMLS CUI [2,2])
history of clinically significant gastrointestinal, hepatic or cardiovascular disease
Item
history of clinically significant gastrointestinal, hepatic or cardiovascular disease
boolean
C0262926 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
C0017178 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0007222 (UMLS CUI [4])
C0009488 (UMLS CUI [1,2])
C0017178 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0007222 (UMLS CUI [4])
active proliferative diabetic retinopathy
Item
active proliferative diabetic retinopathy
boolean
C0154830 (UMLS CUI [1,1])
C0205177 (UMLS CUI [1,2])
C0205177 (UMLS CUI [1,2])
diabetic gastroparesis
Item
history of diabetic gastroparesis
boolean
C0267176 (UMLS CUI [1])
steroid therapy
Item
concurrent use of systemic corticosteroid
boolean
C0149783 (UMLS CUI [1])